Helicid: A novel Anti-Staphylococcus aureus adjuvant.

Area of Science:

• Microbiology
• Biochemistry
• Pharmacology

Background:

• Staphylococcus aureus (S. aureus) poses a significant threat due to its virulence factors, such as staphylocoagulase (Coa).
• Developing novel strategies to combat S. aureus infections, including adjunctive therapies, is crucial.

Purpose of the Study:

• To elucidate the mechanism by which helicid (HEL) suppresses Coa.
• To evaluate the synergistic effects of HEL with antibiotics against S. aureus.
• To establish HEL's potential as an antibacterial adjuvant.

Main Methods:

• Coagulation and biofilm assays were used to assess HEL's impact on S. aureus pathogenicity.
• Thermal shift assay, molecular dynamics simulations, and fluorescence quenching validated HEL-Coa interaction.
• Molecular docking and point mutation assays identified key binding sites.
• Antibiotic synergy tests and resistance induction assays evaluated HEL combined with ceftaroline fosamil (CEF-F).
• In vivo studies in Galleria mellonella and mice assessed therapeutic efficacy and inflammatory responses.

Main Results:

• HEL directly binds to Coa, stabilizing the protein (6°C ΔTm at 100 μM) and inhibiting S. aureus virulence.
• HEL potentiates the bactericidal activity of CEF-F and reduces S. aureus resistance to this antibiotic.
• Combined HEL and CEF-F treatment decreased bacterial load, improved survival in animal models, and reduced pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ).

Conclusions:

• HEL directly targets and inhibits the S. aureus virulence factor Coa.
• HEL acts as an effective antibacterial adjuvant, enhancing the efficacy of CEF-F against S. aureus.
• The HEL-CEF-F combination offers a promising therapeutic strategy for S. aureus-induced pneumonia, reducing lethality and antibiotic resistance.